MX2020008103A - Metodos y composiciones para polarizacion de macrofagos. - Google Patents

Metodos y composiciones para polarizacion de macrofagos.

Info

Publication number
MX2020008103A
MX2020008103A MX2020008103A MX2020008103A MX2020008103A MX 2020008103 A MX2020008103 A MX 2020008103A MX 2020008103 A MX2020008103 A MX 2020008103A MX 2020008103 A MX2020008103 A MX 2020008103A MX 2020008103 A MX2020008103 A MX 2020008103A
Authority
MX
Mexico
Prior art keywords
compositions
methods
macrophage polarization
disclosed
polarization
Prior art date
Application number
MX2020008103A
Other languages
English (en)
Inventor
Sriram Sathyanarayanan
Douglas E Williams
Dalia Burzyn
Adam Thomas Boutin
Sushrut Kamerkar
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MX2020008103A publication Critical patent/MX2020008103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen composiciones y métodos que comprenden vesículas extracelulares que comprenden ácido nucleico que se dirige a genes, lo que conduce a la polarización de macrófagos de macrófagos asociados a tumores. En ciertas modalidades, en la presente se describen métodos y composiciones para aumentar la polarización de macrófagos para el tratamiento del cáncer.
MX2020008103A 2018-02-12 2019-02-12 Metodos y composiciones para polarizacion de macrofagos. MX2020008103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862629563P 2018-02-12 2018-02-12
PCT/US2019/017731 WO2019157535A1 (en) 2018-02-12 2019-02-12 Methods and compositions for macrophage polarization

Publications (1)

Publication Number Publication Date
MX2020008103A true MX2020008103A (es) 2020-09-25

Family

ID=65729420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008103A MX2020008103A (es) 2018-02-12 2019-02-12 Metodos y composiciones para polarizacion de macrofagos.

Country Status (17)

Country Link
US (2) US11512315B2 (es)
EP (1) EP3752615A1 (es)
JP (1) JP2021512608A (es)
KR (1) KR20200120624A (es)
CN (1) CN111918967A (es)
AU (1) AU2019218991A1 (es)
BR (1) BR112020016228A2 (es)
CA (1) CA3088009A1 (es)
CL (1) CL2020002053A1 (es)
CO (1) CO2020009694A2 (es)
EA (1) EA202091486A1 (es)
IL (1) IL276409A (es)
MX (1) MX2020008103A (es)
PH (1) PH12020551195A1 (es)
SG (1) SG11202006021SA (es)
TW (1) TW202003846A (es)
WO (1) WO2019157535A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3752615A1 (en) 2018-02-12 2020-12-23 Codiak BioSciences, Inc. Methods and compositions for macrophage polarization
WO2020106771A1 (en) * 2018-11-19 2020-05-28 Exosome Therapeutics, Inc. Compositions and methods for producing exosome loaded therapeutics for the treatment of multiple oncological disorders
WO2021030769A1 (en) * 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with nras antisense oligonucleotides
US20230018254A1 (en) * 2019-08-14 2023-01-19 Codiak Biosciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
BR112022002599A2 (pt) * 2019-08-14 2022-07-19 Codiak Biosciences Inc Vesícula extracelular ligada a moléculas e usos da mesma
AU2020330133A1 (en) * 2019-08-14 2022-03-17 Lonza Sales Ag Extracellular vesicle-ASO constructs targeting CEBP/beta
EP4013877A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting stat6
US20240099973A1 (en) * 2019-09-25 2024-03-28 Lonza Sales Ag Extracellular vesicle compositions
CN115297850A (zh) * 2019-12-05 2022-11-04 得克萨斯州大学***董事会 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗
WO2021237100A1 (en) * 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN111748523B (zh) * 2020-07-17 2022-11-22 南通大学 一种免疫调节小胞外囊泡的制备方法及其用途
WO2022076596A1 (en) * 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN113262305B (zh) * 2021-05-27 2022-03-25 浙江大学 Coro1a基因作为靶点在制备抗肿瘤药物中的应用
AU2022300794A1 (en) 2021-07-02 2024-01-18 Spark Biopharma, Inc Novel benzopyran derivative and use thereof
CN113521252B (zh) * 2021-07-29 2022-12-20 南开大学 Tnfsf15蛋白作为巨噬细胞免疫增强剂的用途及其活化方法
WO2023069628A2 (en) * 2021-10-21 2023-04-27 Nanothera Biosciences, Inc. Compositions and methods for silencing kras
CN114058621B (zh) * 2021-12-03 2023-06-16 温州医科大学 一种lncRNA基因修饰细胞分泌的外泌体及应用
CN114209814B (zh) * 2021-12-15 2024-02-23 南开大学 Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途
CN114561347A (zh) * 2022-02-25 2022-05-31 和携科技有限公司 一种脂肪间充质干细胞的培养基和培养方法
CN115137708B (zh) * 2022-06-24 2023-05-16 重庆医科大学 装载yap1核酸序列的肝纤维化靶向纳米颗粒及其制备方法和应用
WO2024015512A1 (en) * 2022-07-13 2024-01-18 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells
CN115261410A (zh) * 2022-07-20 2022-11-01 中山大学 一种基因编辑工程化m1型巨噬细胞外泌体的制备方法及其应用
WO2024044788A2 (en) * 2022-08-26 2024-02-29 Georgia State University Research Foundation, Inc. Treating chronic inflammation and cancer by macrophage polarization
CN115814108A (zh) * 2022-12-27 2023-03-21 华中科技大学 一种用于个性化肿瘤治疗的工程化巨噬细胞载药微颗粒制剂及其制备方法
KR102635831B1 (ko) * 2023-11-01 2024-02-13 강원대학교 산학협력단 Cxcl11에 의한 m2 대식세포의 재분극 유도를 통한 폐섬유화증 치료 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6860201A (en) * 2000-06-19 2002-01-02 Halliburton Energy Serv Inc Apparatus and methods for applying time lapse vsp to monitor a reservoir
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
DE102006050655A1 (de) * 2006-10-24 2008-04-30 Halmon Beheer B.V. Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen
WO2010115206A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
US20140141986A1 (en) * 2011-02-22 2014-05-22 David Spetzler Circulating biomarkers
WO2014082083A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US20160243192A1 (en) * 2013-10-17 2016-08-25 Children's Hospital Los Angeles Antibody dependent exosome therapy
CA2965034C (en) * 2014-10-24 2023-05-02 Astrazeneca Ab Combination of an immunomodulatory agent and an antisense oligonucleotide
AU2016275046B2 (en) * 2015-06-10 2022-07-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
US20180273577A1 (en) * 2015-09-24 2018-09-27 Ionis Pharmaceuticals, Inc. Modulators of kras expression
RU2018136151A (ru) 2016-03-15 2020-04-15 Кодиак Байосайнсиз, Инк. Терапевтические мембранные везикулы
EP3500244A4 (en) 2016-08-22 2020-05-13 Codiak BioSciences, Inc. METHOD FOR SUPPRESSING THE DELIVERY OF EXOSOMES TO LIVER AND SPLEEN
EP3672573A4 (en) 2017-08-25 2021-05-26 Codiak BioSciences, Inc. PRODUCTION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
EP3752615A1 (en) 2018-02-12 2020-12-23 Codiak BioSciences, Inc. Methods and compositions for macrophage polarization
BR112022002599A2 (pt) * 2019-08-14 2022-07-19 Codiak Biosciences Inc Vesícula extracelular ligada a moléculas e usos da mesma
US20210322405A1 (en) * 2020-04-15 2021-10-21 Washington University Compositions and methods for treating cancer
WO2023165615A1 (en) * 2022-03-04 2023-09-07 I-Mab Biopharma Co., Ltd. Combination therapies comprising a kras inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
BR112020016228A2 (pt) 2020-12-08
AU2019218991A1 (en) 2020-07-09
IL276409A (en) 2020-09-30
JP2021512608A (ja) 2021-05-20
KR20200120624A (ko) 2020-10-21
EP3752615A1 (en) 2020-12-23
US20200407725A1 (en) 2020-12-31
SG11202006021SA (en) 2020-08-28
CA3088009A1 (en) 2019-08-15
CL2020002053A1 (es) 2020-12-18
CO2020009694A2 (es) 2020-10-30
CN111918967A (zh) 2020-11-10
US20230365971A1 (en) 2023-11-16
TW202003846A (zh) 2020-01-16
WO2019157535A1 (en) 2019-08-15
EA202091486A1 (ru) 2021-02-08
US11512315B2 (en) 2022-11-29
PH12020551195A1 (en) 2021-08-16

Similar Documents

Publication Publication Date Title
PH12020551195A1 (en) Methods and compositions for macrophage polarization
EP4339287A3 (en) Modified cells and methods of therapy
PH12019501959A1 (en) Therapeutic rna
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PH12017501576B1 (en) Riluzole prodrugs and their use
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
MX2019010039A (es) Composiciones y métodos para transducción de tumores.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
EP3998341A3 (en) Adenoviral vectors
PH12017502216A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2017011298A (es) Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
EP3693022A3 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
WO2016164743A3 (en) Cd38 ligand-drug conjugates for targeted cancer therapy
MY200161A (en) Bacteria for targeting tumors and treating cancer
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.